OBIO Cash-Secured Put Strategy

OBIO (Orchestra BioMed Holdings, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.

OBIO (Orchestra BioMed Holdings, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $237.6M, a beta of 0.52 versus the broader market, a 52-week range of 2.2-5.424, average daily share volume of 202K, a public-listing history dating back to 2020, approximately 70 full-time employees. These structural characteristics shape how OBIO stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 0.52 indicates OBIO has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.

What is a cash-secured put on OBIO?

A cash-secured put sells an out-of-the-money put while holding cash equal to the strike-times-100 obligation, keeping the premium when the underlying stays above the strike.

Current OBIO snapshot

As of May 15, 2026, spot at $3.78, ATM IV 99.00%, IV rank 21.73%, expected move 28.38%. The cash-secured put on OBIO below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.

Why this cash-secured put structure on OBIO specifically: OBIO IV at 99.00% is on the cheap side of its 1-year range, which means a premium-selling OBIO cash-secured put collects less credit per unit of strike-width risk, with a market-implied 1-standard-deviation move of approximately 28.38% (roughly $1.07 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated OBIO expiries trade a higher absolute premium for lower per-day decay. Position sizing on OBIO should anchor to the underlying notional of $3.78 per share and to the trader's directional view on OBIO stock.

OBIO cash-secured put setup

The OBIO cash-secured put below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With OBIO near $3.78, the first option leg uses a $3.59 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed OBIO chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 OBIO shares for the stock leg in covered calls and collars).

ActionTypeStrike / BasisPremium (est)
Sell 1Put$3.59N/A

OBIO cash-secured put risk and reward

Net Premium / Debit
N/A
Max Profit (per contract)
Unbounded
Max Loss (per contract)
Unbounded
Breakeven(s)
None on modeled curve
Risk / Reward Ratio
N/A

Max profit equals premium times 100; max loss equals strike minus premium times 100 (at zero, assuming assignment). Breakeven is strike minus premium.

OBIO cash-secured put payoff curve

Modeled P&L at expiration across a range of underlying prices for the cash-secured put on OBIO. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

When traders use cash-secured put on OBIO

Cash-secured puts on OBIO earn premium while a trader waits to acquire OBIO stock at a target strike below the current quote; most attractive when IV is rich and the trader is comfortable owning OBIO.

OBIO thesis for this cash-secured put

The market-implied 1-standard-deviation range for OBIO extends from approximately $2.71 on the downside to $4.85 on the upside. A OBIO cash-secured put lets a trader earn premium while waiting to acquire OBIO at the strike price; the strategy is most attractive when the trader is comfortable holding the underlying at that level and IV is rich enough to compensate for the assignment risk. Current OBIO IV rank near 21.73% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on OBIO at 99.00%. As a Healthcare name, OBIO options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to OBIO-specific events.

OBIO cash-secured put positions are structurally neutral to slightly bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. OBIO positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move OBIO alongside the broader basket even when OBIO-specific fundamentals are unchanged. Short-premium structures like a cash-secured put on OBIO carry tail risk when realized volatility exceeds the implied move; review historical OBIO earnings reactions and macro stress periods before sizing. Always rebuild the position from current OBIO chain quotes before placing a trade.

Frequently asked questions

What is a cash-secured put on OBIO?
A cash-secured put on OBIO is the cash-secured put strategy applied to OBIO (stock). The strategy is structurally neutral to slightly bullish: A cash-secured put sells an out-of-the-money put while holding cash equal to the strike-times-100 obligation, keeping the premium when the underlying stays above the strike. With OBIO stock trading near $3.78, the strikes shown on this page are snapped to the nearest listed OBIO chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are OBIO cash-secured put max profit and max loss calculated?
Max profit equals premium times 100; max loss equals strike minus premium times 100 (at zero, assuming assignment). Breakeven is strike minus premium. For the OBIO cash-secured put priced from the end-of-day chain at a 30-day expiry (ATM IV 99.00%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a OBIO cash-secured put?
The breakeven for the OBIO cash-secured put priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current OBIO market-implied 1-standard-deviation expected move is approximately 28.38%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a cash-secured put on OBIO?
Cash-secured puts on OBIO earn premium while a trader waits to acquire OBIO stock at a target strike below the current quote; most attractive when IV is rich and the trader is comfortable owning OBIO.
How does current OBIO implied volatility affect this cash-secured put?
OBIO ATM IV is at 99.00% with IV rank near 21.73%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.

Related OBIO analysis